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Objectives The aim of this study was to investigate the efﬁcacy of a paclitaxel-eluting balloon (PEB)
for the treatment of sirolimus-eluting stent (SES) restenosis.
Background Because drug-eluting stents (DES) are being used in increasingly complicated settings,
DES restenosis is no longer an uncommon phenomenon, and its optimal treatment is unknown.
Methods This study was a prospective single-blind randomized trial conducted in 50 patients with
SES restenosis. Patients were randomly assigned to a PEB group (n  25) or a conventional balloon
angioplasty (BA) group (n  25). The primary end point was late lumen loss at 6-month follow-up.
Secondary end points included the rate of binary restenosis (in-segment analysis) and major adverse
cardiac events (MACE) at 6-month follow-up.
Results At 6-month angiographic follow-up (follow-up rate: 94%), in-segment late lumen loss was
lower in the PEB group than in the BA group (0.18  0.45 mm vs. 0.72  0.55 mm; p  0.001). The
incidence of recurrent restenosis (8.7% vs. 62.5%; p  0.0001) and target lesion revascularization
(4.3% vs. 41.7%; p  0.003) was also lower in the PEB group than in the BA group. The cumulative
MACE-free survival was signiﬁcantly better in the PEB group than in the BA group (96% vs. 60%;
p  0.005).
Conclusions In patients with SES restenosis, PEB provided much better clinical, angiographic out-
comes than conventional BA. (J Am Coll Cardiol Intv 2011;4:149–54) © 2011 by the American
College of Cardiology Foundation
From the Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan. All authors have reported that they have no
relationships to disclose.Manuscript received August 10, 2010; revised manuscript received October 14, 2010, accepted October 17, 2010.
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150Drug-eluting stents (DES) have dramatically reduced the
restenosis risk compared with bare-metal stents (BMS) and
conventional balloon angioplasty (BA) (1,2). Because DES
are being used in increasingly complicated settings, DES
restenosis is no longer an uncommon phenomenon, and its
optimal treatment is unknown. Recently, DES have come
to be considered the standard treatment for coronary in-
stent restenosis (ISR). However, recent studies with DES
have demonstrated higher rates of recurrent restenosis and
recurrent target lesion revascularization (TLR) when used
for the treatment of DES restenosis compared with the
treatment of de novo lesions (3–5). Furthermore, repeat
stenting for DES restenosis is associated with a high risk of
treatment failure (6). In a pilot prospective double-blind
randomized trial, the treatment of BMS restenosis with a
paclitaxel-eluting balloon (PEB) catheter revealed a surpris-
ingly lower late lumen loss at 6 months and fewer major
adverse cardiac events (MACE) for up to 2 years compared
with conventional BA (7,8).
However, currently no data are
available to support PEB in the
treatment of DES restenosis.
The aim of this study was to
investigate the efficacy of PEB
for the treatment of sirolimus-
eluting stent (SES) restenosis.
Methods
Patient selection and study
design. Patients with ISR after
SES implantation treated at our
institute between September
2008 and November 2009 were
enrolled in this study. Eligible
patients were not younger than
8 years of age and had clinical evidence of stable angina.
atients with acute coronary syndrome, severe renal insuf-
ciency (glomerular filtration rate 30 ml/min), prior stent
mplantation within 6 months, severe concomitant systemic
llness, and conditions likely to preclude follow-up angiog-
aphy were excluded. The target lesion had to be the first
SR after SES implantation with a restenosis length of 26
m in a vessel 2.5 to 3.5 mm in diameter. Lesions in the left
ain coronary artery and ostial, bifurcated, or totally oc-
luded lesions were not regarded as target lesions.
Patients were randomly assigned to a PEB group or a
onventional BA group by means of sealed envelopes contain-
ng a randomization schedule generated by a computer before
he beginning of the study. This study was designed as a
ingle-blind study, and the patients were blinded to the
reatment assignment during the study. The study was con-
ucted in accordance with the provisions of the Declaration of
Abbreviations
and Acronyms
BA  balloon angioplasty
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
ISR  in-stent restenosis
MACE  major adverse
cardiac event(s)
MLD  minimal lumen
diameter
PEB  paclitaxel-eluting
balloon
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularizationelsinki and local regulations. The protocol was approved by lhe institutional review board, and written informed consent
as obtained from all patients before randomization. All pa-
ients were requested to undergo repeat angiography 6 months
fter a successful procedure.
Interventional procedure. All patients received prior treat-
ment of aspirin (100 mg daily) and ticlopidine (200 mg/day)/
clopidogrel (75 mg/day). Aspirin treatment was prescribed
for life. Ticlopidine/clopidogrel treatment was recom-
mended for at least 3 months. During interventions, heparin
was administered to maintain an activated clotting time of
more than 250 s. Pre-dilation was performed at all sites of
ISR lesions. The recommended inflation time for PEB was
60 s. A paclitaxel-eluting PTCA balloon (SeQuent Please
balloon catheter; B. Braun Melsungen AG, Vascular Sys-
tems, Berlin, Germany) was available in 15-, 20-, 26-, and
30-mm lengths and in diameters of 2.5, 3.0, and 3.5 mm.
Angiographic analysis. Serial coronary angiography was
erformed at baseline (before and after intervention) and at
-month follow-up. Quantitative coronary angiographic
nalysis was performed with QCA-CMS (Medis Medical
maging Systems, Leiden, the Netherlands). All angiograms
ere analyzed in a random sequence by 2 experienced
bservers who were blinded to the clinical characteristics of
he patients. Coronary angiograms were obtained in multi-
le views after intracoronary nitrate. Reference diameter,
inimal lumen diameter (MLD), percentage diameter ste-
osis, and lesion length were measured before and after
ntervention and at follow-up. Acute gain was defined as
LD immediately after the procedure minus MLD at
aseline. Late lumen loss was defined as MLD immediately
fter the procedure minus MLD at angiographic follow-up.
easurements included the stenotic area (from shoulder to
houlder where the balloon was dilated; in-lesion analysis)
nd the total treated area plus 5 mm of the edge (in-segment
nalysis).
Follow-up and deﬁnition. Clinical and angiographic follow-up
as performed routinely 6 months after a successful proce-
ure. The follow-up angiogram was obtained earlier if
linically indicated. Binary restenosis at follow-up was
efined as a stenosis occupying more than 50% of diameter.
he ISR was classified as focal (type I, 10 mm in length),
iffuse (type II, 10 mm in length), proliferative (type III,
10 mm in length and extending outside the stent), or
otally occluded (type IV) according to the Mehran classi-
cation (9). The TLR was defined as any repeat percuta-
eous coronary intervention or aortocoronary bypass surgery
ue to restenosis (percentage diameter stenosis 50%)
ssociated with symptoms or objective signs of ischemia.
eath from any cause, nonfatal repeat acute myocardial
nfarction, and TLR were considered MACE. Stent throm-
osis was defined according to Academic Research Consor-
ium guidelines (10).
Study end points. The primary end point was late lumen
oss at 6-month follow-up. Secondary end points included
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151the rate of binary restenosis (in-segment analysis) and
MACE at 6-month follow-up.
Statistical analysis. Continuous variables are expressed as
mean  SD. Values are reported as numbers with relative
percentage or SD. For continuous data, groups were
compared with a parametric Student t test or a nonpara-
metric Mann-Whitney U test according to the distribu-
tion of the data. Categorical variables were compared
with a chi-square test. A p value of 0.05 was considered
statistically significant. Survival curves were constructed
by the Kaplan-Meier method. The SPSS statistical soft-
ware (version 17.0, SPSS, Inc., Chicago, Illinois) was
used for all statistical calculations.
Results
Baseline and procedural data. Fifty patients with ISR of
ES were enrolled and randomly assigned to a PEB
roup (n  25) or BA group (n  25) (Fig. 1). Table 1
hows baseline clinical, angiographic, and procedural
haracteristics. No significant differences were observed
n clinical characteristics between the 2 groups except for
ex. Forty-two percent of the lesions had nonfocal ISR.
he types of ISR in the PEB group were similar to those
n the BA group. Post-intervention MLD was also similar
1.99  0.26 mm vs. 2.00  0.51 mm; p  0.912)
etween the groups. Procedural success was obtained in
Figure 1. Flow Chart of Patients Enrolled in Trial and
Patients Receiving Angiographic and Clinical Follow-UpPts  patients; SES  sirolimus-eluting stent(s).ll patients (100%). No major events occurred during
ospital stay.
Angiographic results. Follow-up angiography was per-
ormed in 47 patients at an average of 184  27 days after
ntervention (follow-up rate: 94%); 3 remaining patients
efused follow-up angiography. Quantitative coronary an-
iographic results are summarized in Table 2. The incidence
f recurrent restenosis was 8.7% (2 of 23 lesions) in the PEB
roup and 62.5% (15 of 24 lesions) in the BA group (p 
.0001) (Fig. 2). The incidence of TLR was 4.3% (1 of 23
esions) in the PEB group and 41.7% (10 of 24 lesions) in
he BA group (p  0.003) (Fig. 2). The in-segment late
umen loss was lower in the PEB group than in the BA
roup (0.18  0.45 mm vs. 0.72  0.55 mm; p  0.001).
ecurrent restenosis occurred in 7 of 8 nonfocal restenosis
esions in the BA group and in 2 of 11 lesions in the PEB
roup (Fig. 2). With regard to both focal and nonfocal
estenosis, the cumulative incidence in the PEB group was
ignificantly lower than that in the BA group (Fig. 3).
Clinical outcomes. A complete clinical follow-up at 6
Table 1. Baseline Clinical, Angiographic, and Procedural Characteristics
PEB Group
(n  25)
BA Group
(n  25) p Value
Age, yrs 69.9 11.0 68.9 9.9 0.74
Male 19 (76) 24 (96) 0.049
Risk factors
Diabetes mellitus 14 (56) 17 (68) 0.38
Hypertension 15 (60) 17 (68) 0.56
Hyperlipidemia 15 (60) 16 (64) 0.77
Current smoker 1 (4) 0 (0) 0.50
Previous MI 8 (32) 14 (56) 0.09
Target lesion 0.22
Left anterior descending 16 (64) 11 (44)
Left circumﬂex 2 (8) 6 (24)
Right 7 (28) 8 (32)
Classiﬁcation of ISR 0.67
Type I 13 (52) 16 (64)
Type II 9 (36) 8 (32)
Type III 3 (12) 1 (4)
Type IV 0 (0) 0 (0)
Procedural characteristics
Angiographic success 25 (100) 25 (100) 1.00
Pre-dilation
Balloon diameter (mm) 2.78 0.39 2.91 0.48 0.39
Balloon length (mm) 16.0 2.2 16.0 3.0 0.91
Paclitaxel-eluting balloon
Balloon diameter (mm) 2.74 0.39
Balloon length (mm) 20.5 4.1
TIMI ﬂow grade 3 after procedure 25 (100) 25 (100) 1.00
Values are mean SD or n (%), unless otherwise indicated.
BA conventional balloon angioplasty; ISR in-stent restenosis; MImyocardial infarction;
PEB paclitaxel-eluting balloon; TIMI Thrombolysis In Myocardial Infarction.months was conducted for all 50 patients (100%). All
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152patients had received aspirin (100 mg/day) and ticlopidine
(200 mg/day)/clopidogrel (75 mg/day) during the 6-month
follow-up period. No death, myocardial infarction, or stent
thrombosis occurred in any group. The Kaplan-Meier
MACE-free survival curve is shown in Figure 4. The
cumulative MACE-free survival was significantly better in
the PEB group than in the BA group (log-rank test; p 
0.005). The MACE-free rate during 6-month follow-up
in the PEB and BA groups was 96% and 60%, respec-
Table 2. Quantitative Coronary Angiographic Analysis Results
PEB Group
(n  25)
BA Group
(n  25) p Value
Before procedure
Percentage diameter stenosis (%) 64.1 9.9 68.4 16.9 0.77
MLD 0.99 0.32 0.92 0.51 0.84
Reference diameter 2.69 0.36 2.90 0.47 0.11
Lesion length 12.7 5.3 13.2 5.5 0.66
After procedure
Percentage diameter stenosis (%) 25.7 7.2 31.0 8.9 0.024
MLD 1.99 0.26 2.00 0.51 0.91
Reference diameter 2.74 0.34 2.90 0.46 0.25
Acute gain 1.03 0.31 1.10 0.54 0.71
6-month follow-up 23/25 (92%) 24/25 (96%)
Percentage diameter stenosis (%) 34.2 15.2 58.0 22.7 0.0001
MLD (in-lesion) 1.82 0.54 1.28 0.80 0.010
MLD (in-segment) 1.81 0.54 1.28 0.80 0.011
Reference diameter 2.74 0.36 2.98 0.47 0.09
Late luminal loss (in-lesion) 0.17 0.45 0.72 0.56 0.001
Late luminal loss (in-segment) 0.18 0.45 0.72 0.55 0.001
Binary restenosis 2 (8.7) 15 (62.5) 0.0001
Target lesion revascularization) 1 (4.3) 10 (41.7) 0.003
Values are mean SD or n (%), and are given in millimeters, unless otherwise indicated.
MLDminimal lumen diameter; abbreviations as in Table 1.
Figure 2. Angiographic Restenosis and TLRTLR  target lesion revascularization.tively, and all MACE were due to repeated revascular-
ization procedures.
Discussion
This randomized study demonstrated that PEB for treat-
ment of SES restenosis was effective and resulted in a low
late lumen loss and a low incidence of recurrent restenosis.
In a previous study, Scheller et al. (7,8) treated BMS
restenosis with PEB or conventional BA and compared the
angiographic outcomes. Compared with conventional BA,
PEB exhibited a significant reduction in 6-month late lumen
loss and angiographic restenosis. In addition, PEB was asso-
ciated with a significant reduction in MACE. There are no
published data concerning the effects of PEB on DES reste-
nosis. In our study, we found an incidence of angiographic
restenosis of 8.7% and 62.5% (p  0.0001) and a mean late
lumen loss of 0.18 mm and 0.72 mm (p  0.001) in the PEB
nd BA groups, respectively. In a previous randomized trial in
atients with BMS restenosis, the angiographic restenosis rate
as 6% to 7% and 51%, and the mean late lumen loss was 0.11
o 0.17 and 0.81 mm, in the PEB and conventional BA
roups, respectively (7,8,11). The results of our study are
onsistent with those of the aforementioned publications. Our
tudy suggests that PEB could be effective for different biolog-
cal responses after DES restenosis.
Taking angiographic patterns of restenosis into consid-
ration is important when assessing DES restenosis. Pa-
ients with a nonfocal pattern of DES restenosis have a
igher rate of repeat DES implantation than those with a
ocal pattern (12). In our study, 42% of lesions were
onfocal restenosis. In nonfocal lesions, there was a highly
significant difference in recurrent restenosis between the 2
groups (18% in the PEB group vs. 88% in the BA group; p
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1530.005). In the PEB group, no recurrence was observed in
focal restenosis. The PEB might be more effective for the
treatment of nonfocal DES restenosis.
Post-DES restenosis is associated with poorer outcomes
than post-BMS restenosis (13,14). The DES is an excellent
treatment for patients with BMS restenosis but not always
for patients with DES restenosis. The mechanisms of DES
restenosis are similar to those of BMS restenosis, including
stent underexpansion, stent fracture, stent malapposition,
and nonuniform strut distribution (15–18). In addition, the
particular mechanisms of DES restenosis include several
drug-specific factors, such as localized hypersensitivity, non-
uniform drug deposition, polymer disruption due to difficult
stent delivery, and drug resistance (19).
A number of studies have investigated repeat DES
Figure 3. Cumulative Incidence of Restenosis During
6-Month Follow-Up Period
Cumulative incidence of restenosis during the 6-month follow-up period:
focal (A) versus nonfocal (B) lesions.implantation for patients with DES restenosis, and theprocedure is currently considered an option for DES reste-
nosis treatments. However, repeat stenting has the follow-
ing limitations: 1) nonresorbable polymers trigger chronic
inflammation and hypersensitivity reactions that might
contribute to increased risks of late stent thrombosis and
late restenosis (20,21); 2) repeat stenting might lead to
uneven distribution of drug release and suboptimal stent
geometry (18); 3) repeat stenting might cause insufficient
stent expansion, which has been shown to be predictive of
recurrent restenosis (22); and 4) repeat stenting is problem-
atic because treatment of recurrent restenosis is limited,
because of multiple layers of metal in the coronary artery. A
PEB allows for immediate and homogenous drug transfer to
the vessel wall without any polymers or sustained-release
mechanism. The absence of a stent ensures that the original
anatomy of the arteries is not altered. A PEB could be used
multiple times if recurrent restenosis occurred. From this
point of view, PEB might be the next preferred strategy for
the treatment of DES restenosis.
Study limitations. This was a single-center randomized trial
with a relatively small number of patients. In a pilot
prospective double-blind randomized trial, PEB treatment
was associated with fewer MACE than conventional BA at
6- to 24-month follow-ups (8). Therefore, we followed up
our patients for 6 months. However, the optimal time point
for evaluation of PEB efficacy for DES restenosis remains to
be defined. The clinical and angiographic follow-ups were
limited to 6 months, and further long-term information is
eagerly awaited.
We regarded the patients receiving conventional BA as
the control group in this study, because the optimal treat-
ment strategy for DES restenosis has not yet been ade-
quately defined. In a previous study with SES restenosis, the
restenosis rate was 19% to 20%, and the mean late lumen
loss was 0.38 to 0.40 mm in the repeat stenting group (23).
Figure 4. Kaplan-Meier MACE-Free Survival Curve for 6-Month Follow-UpMACE  major adverse cardiac event(s).
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154This suggested that PEB could be more effective for DES
restenosis than repeat stenting. However, we should con-
duct a randomized study to compare PEB with repeat
stenting for the management of DES restenosis.
Conclusions
This randomized clinical study suggested that PEB pro-
vided much better clinical, angiographic outcomes than
conventional BA in patients with SES restenosis.
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